Skip to content

house · Committee report

H. Rept. 118-50

TESTING, RAPID ANALYSIS, AND NARCOTIC QUALITY RESEARCH ACT

2023-05-05

Committees

Associated legislation

Text

Purpose and Summary

The National Institute of Standards and Technology (NIST) has unique analytical capabilities in the safe handling and identification of illicit drugs. This legislation would direct NIST to take steps to enhance its work to understand the unique properties of Tranq and other novel synthetic opioids, develop new analytical capabilities for novel synthetic opioids, and establish new partnerships with front-line entities that are oftentimes the points of first contact for new opioid variants.

Background and Need for Legislation

The development and distribution of novel synthetic opioids continues to threaten the health and safety of communities across the United States. A new fentanyl analogue, commonly known as ``Tranq'', containing a veterinary tranquilizer, xylazine, has begun to spread across the country. Many law enforcement agencies, especially in rural America, lack the technical expertise and resources to safely handle dangerous substances. While local law enforcement and non-profit agencies on the East Coast are relatively familiar with the utility of working with NIST, the agency's work is lesser known as you move west across the country. The Drug Enforcement Agency (DEA) reports skyrocketing detections of xylazine, with growth between 2020 and 2021 at 61% in the Northeast, 198% in the South, 7% in the Midwest, and 112% in the West. According to the DEA, ``the presence of xylazine in illicit drug combinations and its detection in fatal overdoses may be more widespread than reported as a number of jurisdictions across the country may not include xylazine in forensic laboratory or toxicology testing.'' Directing NIST to leverage its existing expertise and infrastructure to augment the capabilities of entities working to counter the opioid crisis will save money for local law enforcement, enhance safety for law enforcement personnel, raise awareness of the dangers of fentanyl containing xylazine, and better prepare first responders for rapid and safe opioid response activities. LEGISLATIVE HISTORY On March 23, 2023, Rep. Mike Collins and Rep. Yadira Caraveo introduced H.R. 1734, the Testing, Rapid Analysis, and Narcotic Quality (TRANQ) Research Act. On March 29, 2023, the Committee on Science, Space, and Technology met to consider H.R. 1734. Chairman Lucas moved that Committee favorably report the bill, H.R. 1734, as amended, to the House of Representatives with the recommendation that the bill be approved. The motion was agreed to by a vote of 36-0. COMMITTEE VIEWS The Committee recognizes the impact of the opioid crisis on everyday Americans and first responders tasked with providing emergency services to those in need. The Committee is also aware of the unique capabilities of NIST to identify chemical markers of novel synthetic opioids and develop safe handling practices that can inform first response efforts. The Committee encourages NIST to continue its work with novel synthetic opioids and other illicit drugs and to grow its partnerships with first responders across the nation who could benefit from NIST's expertise. SECTION-BY-SECTION Section 1. Short title This section establishes that this legislation may be referred to as the ``Testing, Rapid Ananysis, and Narcotic Quality Research Act'' or the ``TRANQ Research Act.'' Section 2. Xylazine detection and analysis This section directs NIST to conduct basic science and research on illicit drugs, with a special focus on drugs containing xylazine. It also directs NIST to work towards near- real time identification capabilities of xylazine in drugs, convene stakeholders with unique knowledge or interests in counter-opioid efforts, establish collaborative partnerships with other institutions, including research institutions, and provide opportunities for graduate and post-graduate research on xylazine-laced drugs. In fulfilling the requirements of this section, NIST must ensure there are appropriate research security controls. Section 3. Report NIST must submit a report to the Committee on Science, Space, and Technology one year after the date of enactment on the implementation of this act, including legislative recommendations for improving NIST's ability to carry out the act. EXPLANATION OF AMENDMENTS An amendment offered by Representative Claudia Tenney was adopted by voice vote and is incorporated in the Committee reported text of H.R. 1734. The amendment requires NIST to report on the effectiveness of the legislation one year after enactment, and allows NIST to include recommendations for how to improve the effort as part of the reporting requirement. This amendment is consistent with the spirit of the legislation and will inform Congressional oversight of NIST's efforts in the future.

Committee Consideration

On March 29, 2023, the Committee met in open session and ordered reported favorably the bill, H.R. 1734, as amended, by roll call vote, a quorum being present. ROLL CALL VOTES Clause 3(b) of rule XIII requires the Committee to list the record votes on the motion to report legislation and amendments thereto. The following reflects the record votes taken during the Committee consideration: [GRAPHIC(S) NOT AVAILABLE IN TIFF FORMAT] APPLICATION OF LAW TO THE LEGISLATIVE BRANCH The Committee finds that H.R. 1734 does not relate to the terms and conditions of employment or access to public services or accommodations within the meaning of section 102(b)(3) of the Congressional Accountability Act (Public Law 104-1). STATEMENT OF OVERSIGHT FINDINGS AND RECOMMENDATIONS OF THE COMMITTEE In compliance with clause 3(c)(1) of rule XIII and clause (2)(b)(1) of rule X, the Committee's oversight findings and recommendations are reflected in the descriptive portions of this report. STATEMENT OF GENERAL PERFORMANCE GOALS AND OBJECTIVES In accordance with clause 3(c)(4) of rule XIII, H.R. 1734 would expand upon NIST's current research and testing of novel synthetic opiods and other illicit drugs, including xylazine, in order to continue to grow its partnerships with first responders across the nation and to develop safety practices which will inform those first response efforts. A yearly reporting requirement ensures that the goals of the Committee are being met and provides an avenue for recommending legislation to improve NIST's ability to carry out these goals. DUPLICATION OF FEDERAL PROGRAMS Pursuant to clause 3(c)(5) of rule XIII, the Committee finds that no provision of H.R. 1734 establishes or reauthorizes a program of the Federal Government known to be duplicative of another Federal program, including any program that was included in a report to Congress pursuant to section 21 of Public Law 111-139 or identified in the most recent Catalog of Federal Domestic Assistance. FEDERAL ADVISORY COMMITTEE ACT The Committee finds that the legislation does not establish or authorize the establishment of an advisory committee within the definition of section 5(b) of the Federal Advisory Committee Act. UNFUNDED MANDATE STATEMENT The Committee adopts as its own the estimate of Federal mandates prepared by the Director of the Congressional Budget Office pursuant to section 423 of the Unfunded Mandates Reform Act. EARMARK IDENTIFICATION Pursuant to clauses 9(e), 9(f), and 9(g) of rule XXI, the Committee finds that H.R. 1734 does not include any congressional earmarks, limited tax benefits, or limited tariff benefits. COMMITTEE COST ESTIMATE Pursuant to clause 3(d)(1) of rule XIII, the Committee adopts as its own the cost estimate prepared by the Director of the Congressional Budget Office pursuant to section 402 of the Congressional Budget Act of 1974. At the time this report was filed, the estimate was not available. NEW BUDGET AUTHORITY, ENTITLEMENT AUTHORITY, AND TAX EXPENDITURES Pursuant to clause 3(c)(2) of rule XIII, the Committee finds that H.R. 1734 would result in no new or increased budget authority, entitlement authority, or tax expenditures or revenues. CONGRESSIONAL BUDGET OFFICE COST ESTIMATE Pursuant to clause 3(c)(3) of rule XIII, at the time this report was filed, the cost estimate prepared by the Director of the Congressional Budget Office pursuant to section 402 of the Congressional Budget Act of 1974 was not available. [all]

Source: https://api.congress.gov/v3/committee-report/118/hrpt/50